作者: De Jesús Espinosa, Aixa ; Turnbull, Marion T ; Cowart, Jennifer B ; Vázquez-Medina, Adriana ; Lesser, Elizabeth ; Weinshilboum, Richard ; Ross, Owen A ; Meschia, James F ; James, Courtney L ; Freeman, W David ; Carter, Rickey E ; Miller, David A

Nimodipine, an L-type cerebroselective calcium channel antagonist, is the only drug approved by the US Food and Drug Administration for the neuroprotection of patients with aneurysmal subarachnoid hemorrhage (aSAH). Four randomized, placebo-controlled trials of nimodipine demonstrated clinical improvement over placebo; however, these occurred before precision medicine with pharmacogenomics was readily available. The standard enteral dose of nimodipine recommended after aSAH is 60 mg every 4 h. However, up to 78% of patients with aSAH develop systemic arterial hypotension after taking the drug at the recommended dose, which could theoretically limit its neuroprotective role and worsen cerebral perfusion pressure and cerebral blood flow, particularly when concomitant vasospasm is present. We investigated the association between nimodipine dose changes and clinical outcomes in a consecutive series of 150 patients (mean age, 56 years; 70.7% women) with acute aSAH. We describe the pharmacogenomic relationship of nimodipine dose reduction with clinical outcomes. These results have major implications for future individualized dosing of nimodipine in the era of precision medicine.

2024-07-01·SCIENCE PROGRESS

1,4-Diol Hq (TBHQ) vs 1,4-dithiol (TBDT); simulation of safe antioxidant with a lower carcinogenic activity

Article

作者: Mosavi, Seyed Zahra ; Zahedi, Tahereh ; Seyedalipour, Bagher ; Colagar, Abasalt Hosseinzadeh

Objectives::

tert-Butylhydroquinone (TBHQ) is an antioxidant and preservative used in unsaturated vegetable oils and processed foods. However, when consumed in higher doses daily, it may pose a threat to public health by potentially increasing the risk of cancer, as it has an affinity with both the aryl hydrocarbon receptor (AhR) and the estrogen receptor alpha (ERα).

Methods::

This study aimed to examine the impact of substituting the 1,4-diol of TBHQ with 1,4-dithiol, referred to as TBDT, on the carcinogenic and antioxidant systems using computational methods. The binding affinity of TBHQ and TBDT to the two carcinogenic receptors, AhR and ERα, as well as to the antioxidant receptor Keap1 alone and in connection with Nrf2 (Nrf2-Keap1) was investigated through docking analysis.

Results::

The results indicated a decrease in TBDT's binding strength to ERα and AhR when assessed using Molegro Virtual Docker ( P-value: 0.0001 and 0.00001, respectively), AutoDock Vina ( P-value: 0.0001 and 0.0001), and the online server Fast DRH ( P-value: 0.0001 and 0.0001). However, TBDT's binding affinity to Keap1 was predicted to be significantly stronger than TBHQ's by both MVD and AutoDock Vina ( P-value: 0.0001 and 0.04), while its binding to Nrf2-Keap1 assessed to be stronger only by MVD ( P-value: 0.0001).

Conclusion::

These findings suggest that TBDT not only exhibits higher antioxidant activity as a better ligand for the antioxidant system but also shows lower affinity with the AhR and ERα receptors. Therefore, TBDT can be considered a safer compound than TBHQ.

2024-01-01·Pharmacoepidemiology and drug safety

Drug‐induced orthostatic hypotension: Cluster analysis of co‐prescription patterns in older people in UK primary care

Article

作者: Petersen, Irene ; Bhanu, Cini ; Sofat, Reecha ; Walters, Kate ; Bazo‐Alvarez, Juan Carlos ; Orlu, Mine ; Davis, Daniel

Abstract:

Purpose:

Over 250 medications are reported to cause orthostatic hypotension, associated with serious adverse outcomes in older adults. Studies suggest a harmful cumulative risk of orthostatic hypotension with multiple medication use. However, there is limited evidence on the potential for harm in practice, particularly which drugs is co‐prescribed and may increase risk of orthostatic hypotension.

Methods:

Retrospective cohort study and cluster analysis using general practice data from IQVIA Medical Research Data (IMRD) in patients aged ≥50 contributing data between 1 January 2018 and 31 December 2018. Thirteen drug groups known to be associated with orthostatic hypotension by mechanism, were analyzed and clusters generated by sex and age‐band.

Results:

A total of 602 713 individuals aged ≥50 with 283 912 (47%) men and 318 801 (53%) women were included. The most prevalent prescriptions that might contribute to orthostatic hypotension were ACE inhibitors, calcium‐channel blockers, beta‐blockers, selective serotonin reuptake inhibitors and uroselective alpha‐blockers. We identified distinct clusters of cardiovascular system (cardiovascular system) drugs in men and women at all ages. cardiovascular system plus psychoactive drug clusters were common in women at all ages, and in men aged ≤70. cardiovascular system plus uroselective alpha‐blockers were identified in men aged ≥70.

Conclusions:

Distinct clusters of drugs associated with orthostatic hypotension exist in practice, which change over the life course. Our findings highlight potentially harmful drug combinations that may cause cumulative risk of orthostatic hypotension in older people. This may guide clinicians about the potential of synergistic harm and to monitor for orthostatic hypotension if using combinations of cardiovascular system drugs, cardiovascular system plus psychoactive drugs and/or alpha‐blockers—particularly in patients aged ≥70 or at high‐risk due to comorbidity. Future research should consider quantifying the risk of drug‐induced orthostatic hypotension with such drug combinations.

项与 TBDT (GLSynthesis) 相关的新闻（医药）

2023-06-23

·PRNewswire

Global Coronary Artery Disease (CAD) Market Worth $38.17 Billion by 2028 - Increasing Demand for Medications Leading to a Rise in Retail Pharmacies

DUBLIN, June 23, 2023 /PRNewswire/ -- The "Coronary Artery Disease (CAD) Market, Size, Global Forecast 2023-2028, Industry Trends, Growth, Share, Outlook, Impact of Inflation, Opportunity Company Analysis" report has been added to ResearchAndMarkets.com's offering. The Global Coronary Artery Disease (CAD) Market will reach US$ 38.17 billion in 2028 from US$ 22.94 billion in 2022, growing at a CAGR of 8.86% The increasing prevalence of CAD due to aging populations, unhealthy lifestyles, and rising rates of obesity and diabetes is driving growth in the coronary artery disease market. Therefore, there is a rising need for diagnostic tools and treatments, such as medication, medical devices, and surgical procedures. Furthermore, advances in medical technology and research have also led to new and more effective therapies for CAD, including drug-eluting stents and minimally invasive procedures. In addition, tailoring treatment plans to individual patients based on their unique factors is becoming increasingly popular, known as personalized medicine. Anti-platelet Drugs Have Hegemony in the Coronary Artery Disease (CAD) Market Drug types in the coronary artery disease (CAD) market are antiplatelets, beta-blockers, calcium antagonists, anticoagulants, and others. Antiplatelet drugs are the dominant therapy in the coronary artery disease market, as they are widely used to prevent blood clots that can lead to heart attacks and strokes in patients with CAD. In addition, they have been proven effective in reducing the risk of recurrent cardiovascular events and have a low risk of side effects, making them a safe long-term option for CAD patients. To manage CAD, use antiplatelet drugs in combination with other therapies such as statins, beta-blockers, and ACE inhibitors. Anticoagulant drugs for coronary artery disease have grown due to various factors. They prevent blood clots in CAD patients, the development of newer medications like DOACs, the increasing prevalence of CAD, and the demand for effective anticoagulant therapies. Personalized medicine has also contributed to growth, as tailored treatment plans can optimize drug use and improve patient outcomes. Increasing Demand for Medications Has Led to the Growth of Retail Pharmacies The coronary artery disease (CAD) market has hospital pharmacies, retail pharmacies, and online pharmacies distribution channels mainly. The growth of retail pharmacies in the coronary artery disease market is due to the increasing demand for medications used in CAD treatment and management, the aging population, and technological advancements. These have expanded retail pharmacies' product offerings and services, making them a more attractive option for patients seeking comprehensive healthcare services. In addition, changes in healthcare policy and reimbursement models have also incentivized patients to seek care in retail pharmacies. However, hospital pharmacies are an authority in the coronary artery disease (CAD) market as they are often the first point of contact for CAD patients, particularly those with acute conditions. They have access to a broader range of medications and specialized products and highly trained professionals with expertise in CAD management. In addition, the trend toward value-based healthcare has led to the development of integrated healthcare systems, making hospital pharmacies integral in providing various services in a single location. China Coronary Artery Disease (CAD) Market has grown because of an aging population and the growing prevalence of chronic ailments like obesity and diabetes. U.S., France, Germany, China, United Kingdom, Japan, Saudi Arabia, and Russia are the countries that comprise the coronary artery disease (CAD) market. Expanding China's healthcare system and investing in medical infrastructure have improved CAD treatment and management. Furthermore, the rise of China's middle class has created opportunities for foreign and domestic pharmaceutical companies to enter the Chinese coronary artery disease (CAD) market. In addition, the government's focus on promoting innovation and research in healthcare has led to new CAD therapies and management strategies, including TCM. Finally, policies promoting healthy lifestyles and disease management programs have contributed to the coronary artery disease (CAD) market growth. The US dominates the CAD market due to its high prevalence of risk factors for CAD, resulting in a significant need for CAD treatments. CAD is the main reason for mortality in the US. The National Centre of Biotechnology Information (NCBI) report of 2023 states that coronary artery disease (CAD) is responsible for approximately 610,000 deaths annually accounting for an estimated 1 in 4 deaths in the United States, making it the leading cause of mortality. The country also has advanced medical infrastructure, leading pharmaceutical and medical device companies, and heavy investment in healthcare research and development. Moreover, the US prioritizes preventive healthcare, focusing more on CAD prevention and management. Key Players AstraZeneca PLC, Novartis AG, Pfizer Inc, Bristol-Myers Squibb Company, Merck & Co. Inc, Viatris, Sanofi, and Amgen are prominent in the coronary artery disease (CAD) market. Company Analysis: Overview, Recent Developments, & Revenue AstraZeneca PLC Novartis AG Pfizer Inc. Bristol-Myers Squibb Company Merck & Co. Inc. Viatris Sanofi Amgen Drug Types - Market breakup from 5 Viewpoints: Antiplatelets Beta-blockers Calcium antagonists Anticoagulants Others Distribution Channels - Market breakup from 3 Viewpoints: Hospital pharmacies Retail pharmacies Online pharmacies Countries - Market breakup from 8 Viewpoints: United States France Germany China United Kingdom Japan Saudi Arabia Russia Clinical Trial Drugs - Overview for 2 Drugs: Colchicine Rivaroxaban 2.5 Mg Oral Tablet For more information about this report visit About ResearchAndMarkets.com ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. Media Contact: Research and Markets Laura Wood, Senior Manager [email protected] For E.S.T Office Hours Call +1-917-300-0470 For U.S./CAN Toll Free Call +1-800-526-8630 For GMT Office Hours Call +353-1-416-8900 U.S. Fax: 646-607-1907 Fax (outside U.S.): +353-1-481-1716 Logo: SOURCE Research and Markets

100 项与 TBDT (GLSynthesis) 相关的药物交易

登录后查看更多信息